ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

Adocia retains the global rights to M1Pram and will continue to evaluate the path forward for M1Pram as the type 1 diabetes treatment landscape continues to evolve

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the expiration of Sanofi’s three-year exclusive right to negotiate a partnership agreement for the development of M1Pram1.

“Although no GLP-1 therapy is currently approved for type 1 diabetes, the rise of GLP-1 therapies has reshaped the obesity treatment landscape. We will continue to assess the opportunity for M1Pram as new treatments continue to evolve. In the meantime, we are focusing on the development of our metabolic peptide delivery platforms, particularly BioChaperone®, the most strategic since it addresses the market’s recent interest in co-formulations and multi-dose formulations,” said Olivier Soula, Chief Executive Officer and Co-founder of Adocia.